D. E. Shaw & Co. Inc. Acquires 114,173 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

D. E. Shaw & Co. Inc. increased its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 18.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 720,105 shares of the biopharmaceutical company's stock after purchasing an additional 114,173 shares during the quarter. D. E. Shaw & Co. Inc. owned 1.18% of Sage Therapeutics worth $3,910,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. Cubist Systematic Strategies LLC bought a new stake in Sage Therapeutics during the 4th quarter worth approximately $829,000. BNP Paribas Financial Markets increased its stake in Sage Therapeutics by 9.3% during the 4th quarter. BNP Paribas Financial Markets now owns 77,560 shares of the biopharmaceutical company's stock worth $421,000 after purchasing an additional 6,574 shares in the last quarter. 683 Capital Management LLC increased its stake in Sage Therapeutics by 5.0% during the 4th quarter. 683 Capital Management LLC now owns 630,000 shares of the biopharmaceutical company's stock worth $3,421,000 after purchasing an additional 30,000 shares in the last quarter. Caligan Partners LP bought a new stake in Sage Therapeutics during the 4th quarter worth approximately $16,575,000. Finally, Jane Street Group LLC increased its stake in Sage Therapeutics by 103.1% during the 4th quarter. Jane Street Group LLC now owns 462,004 shares of the biopharmaceutical company's stock worth $2,509,000 after purchasing an additional 234,528 shares in the last quarter. 99.22% of the stock is owned by institutional investors.

Sage Therapeutics Stock Down 4.6%

Shares of NASDAQ SAGE traded down $0.33 during trading hours on Wednesday, hitting $6.80. The company had a trading volume of 614,217 shares, compared to its average volume of 1,196,317. Sage Therapeutics, Inc. has a 1-year low of $4.62 and a 1-year high of $13.47. The firm's 50 day moving average is $7.38 and its 200-day moving average is $6.73. The stock has a market capitalization of $425.82 million, a P/E ratio of -1.03 and a beta of 0.20.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. The business had revenue of $14.06 million during the quarter, compared to the consensus estimate of $14.12 million. During the same quarter last year, the company posted ($1.80) EPS. The firm's revenue was up 78.0% on a year-over-year basis. On average, sell-side analysts predict that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Scotiabank lowered their target price on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating for the company in a research note on Wednesday, February 12th. Wedbush reaffirmed a "neutral" rating and set a $6.00 price target on shares of Sage Therapeutics in a research report on Wednesday, February 12th. HC Wainwright reaffirmed a "neutral" rating and set a $12.00 price target (down previously from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Bank of America assumed coverage on Sage Therapeutics in a research report on Tuesday, March 11th. They set an "underperform" rating and a $5.00 price target for the company. Finally, StockNews.com downgraded Sage Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, Sage Therapeutics currently has a consensus rating of "Hold" and an average target price of $8.81.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.